These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7118322)

  • 1. Altered hydroxylation rate of triamterene in patients with liver cirrhosis.
    Gundert-Remy U; Müller-Herrmann R; Mutschler E; Schäfer M; Weber E
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):353-7. PubMed ID: 7118322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of triamterene.
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Clin Exp Hypertens A; 1983; 5(2):249-69. PubMed ID: 6831748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Klin Wochenschr; 1983 Sep; 61(18):883-91. PubMed ID: 6632729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of triamterene in the rat.
    Kau ST; Sastry BV; Alvin JD; Bush MT
    Drug Metab Dispos; 1975; 3(5):345-51. PubMed ID: 241615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)].
    Knauf H; Mutschler E; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1417-20. PubMed ID: 582409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triamterene kinetics and dynamics in cirrhosis.
    Villeneuve JP; Rocheleau F; Raymond G
    Clin Pharmacol Ther; 1984 Jun; 35(6):831-7. PubMed ID: 6734036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute severe pancytopenia due to triamterene in alcoholic cirrhotic patients: failure to recognize the pharmacology of triamterene?].
    Denoyel P; Cales P; Grasset D; Huguet-Rigal F; Vinel JP; Pascal JP
    Gastroenterol Clin Biol; 1985 Oct; 9(10):746. PubMed ID: 4065498
    [No Abstract]   [Full Text] [Related]  

  • 12. Abnormal methylation capacity in human liver cirrhosis.
    Geubel AP; Mairlot MC; Buchet JP; Dive C; Lauwerys R
    Int J Clin Pharmacol Res; 1988; 8(2):117-22. PubMed ID: 3378853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Elimination of triamterene, an antikaliuretic, and its phenolic metabolite, 2,4,7-triamino-6-p-hydroxyphenylpteridine, in the urine of subjects with normal liver function and in subjects suffering from liver cirrhosis].
    Andrasch H; Fink T; Schmid E
    Z Gastroenterol; 1971; 9(4):240-5. PubMed ID: 5164739
    [No Abstract]   [Full Text] [Related]  

  • 14. The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death.
    Merkel C; Marchesini G; Fabbri A; Bianco S; Bianchi G; Enzo E; Sacerdoti D; Zoli M; Gatta A
    Hepatology; 1996 Oct; 24(4):820-3. PubMed ID: 8855183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed elimination of triamterene and its active metabolite in chronic renal failure.
    Knauf H; Möhrke W; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(4):453-6. PubMed ID: 6861860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis.
    Lindskov J
    Acta Med Scand; 1982; 212(5):303-8. PubMed ID: 7180580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
    Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
    Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man.
    Gundert-Remy U; von Kenne D; Weber E; Geissler HE; Grebian B; Mutschler E
    Eur J Clin Pharmacol; 1979 Aug; 16(1):39-44. PubMed ID: 499298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.
    Gilfrich HJ; Kremer G; Möhrke W; Mutschler E; Völger KD
    Eur J Clin Pharmacol; 1983; 25(2):237-41. PubMed ID: 6628507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.